A clear relationship, with shared risk factors, exists between diabetes, ED and CVD.
Use of ED as a harbinger of CVD is most predictive in younger men (ED may precede CVD by 2-5 yrs, 3 avg).
The identification of ED may allow for risk reduction and preventative measures in large numbers of men.
To have access to full article that these tools were developed for, please subscribe. The cost to subscribe is $80 USD per year and you will gain full access to all the premium content on www.healthplexus.net, an educational portal, that hosts 1000s of clinical reviews, case studies, educational visual aids and more as well as within the mobile app.
The hallmark of Diabetic Nephropathy is albuminuria. Albuminuria is a marker of poor renal and CV prognosis and should be identified in all patients where CKD is suspected.
Organ protection should be a priority in patients with DN. Very solid evidence exists for the SGTL2i class as it pertains to renal protection. Patients with DN are at very high risk of CV disease and its complications. There are robust data demonstrating CV protection when SGLT2i and GLP-1RAs are used in patients with DKD.
A1C control remains a critical component of preventing the progression of DN and can now be achieved in a safe manner with newer agents that do not cause hypoglycemia.
To have access to full article that these tools were developed for, please subscribe. The cost to subscribe is $80 USD per year and you will gain full access to all the premium content on www.healthplexus.net, an educational portal, that hosts 1000s of clinical reviews, case studies, educational visual aids and more as well as within the mobile app.
Neuropathy is a very common complication of diabetes with sensorimotor neuropathy being the most common subtype of diabetic neuropathy
Other types of diabetic neuropathies include autonomic, treatment-induced, diabetic lumbosacral radiculoplexus, and mononeuropathies
Diagnostic testing for sensorimotor neuropathy includes bedside testing (e.g., Monofilament) and electrodiagnostic methods
Treatment of sensorimotor diabetic neuropathy includes achieving good glycemic control and appropriate use of pain medications
To have access to full article that these tools were developed for, please subscribe. The cost to subscribe is $80 USD per year and you will gain full access to all the premium content on www.healthplexus.net, an educational portal, that hosts 1000s of clinical reviews, case studies, educational visual aids and more as well as within the mobile app.
Good systemic control of blood sugar, hypertension, dyslipidemia and renal function
Timely treatment involving intra-vitreal anti-VEGF injections, laser photocoagulation when appropriate and surgical intervention when necessary
To have access to full article that these tools were developed for, please subscribe. The cost to subscribe is $80 USD per year and you will gain full access to all the premium content on www.healthplexus.net, an educational portal, that hosts 1000s of clinical reviews, case studies, educational visual aids and more as well as within the mobile app.
Why Are Physicians Still Prescribing Sulfonylureas as First Choice for Older Diabetic Adults?
Teaser:
Michael Gordon, MD, MSc, FRCPC, Medical Program Director, Palliative Care, Baycrest Geriatric Health Care System, Professor of Medicine, University of Toronto, Toronto, ON.
Abstract
Diabetes Mellitus is very prevalent in the older population. It is one of the important causes of vascular problems which may play a role in the development of dementia, especially of the mixed variety. There has been much progress in the potential medications that can help promote successful glucose control and address the other metabolic correlates of Type 2 diabetes mellitus. Sulfonylureas should be used rarely and very carefully in older especially frail individuals because of their inherent risks. Getting physicians to change their prescribing practices in this frail elderly diabetic population is an important challenge to educators and drug program administrators. Key Words: diabetes mellitus, sulfonylureas, diabetic management, treatment.